Neumora Therapeutics, Inc. Common Stock

NASDAQ:NMRA

Biotechnology

Healthcare
$0.37 -6.21%

-$0.10 today

Market cap
$69.21M
Beta
2.76
P/E (TTM)
-1.2
EPS (TTM)
-$1.24
52W Low $0.72High $3.65

Volume 1.50M

Average 2.02M

NMRA Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Neumora Therapeutics, Inc. Common StockNASDAQ: NMRA

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 179.87M shares rose 11.4% year over year, ahead of the +4.0% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 10.1% from the prior quarter. Over 3 fiscal years it compounded at +2.4% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +11.4% holds above the trailing-twelve-month pace of +4.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
179.87M+10.1% QoQ
Last fiscal yearDec 2025
163.39M+2.5% YoY
LTMMar 2026
166.7M+4.0% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.4%——
1 year+2.5%——
3-year CAGR+2.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
163.39M USD
Year-over-year change
+2.5%
4-year CAGR
+1.8%

Weighted Avg Shares (Diluted) vs competitors

How NMRA compares with its peers on the latest reported figures

  • NMRA's LTM Mar 2026 weighted avg shares (diluted) of 166.7M shares is the 3rd highest of the 10 companies compared; the peer median is 69.4M shares.
  • Its year-over-year change of +4.0% is the 8th highest of 10, against a peer median of +7.9%.
  • Over three fiscal years its annual growth of +2.4% compares with a peer median of +21.4%.
NMRA Competitors Peer median
Weighted Avg Shares (Diluted) for NMRA and competitors
Company Period LTM YoY 3-year CAGR
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026372.66M +6.8%+29.9%
AUTLAutolus Therapeutics plcLTM Mar 2026266.14M +0.0%+41.0%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026166.7M +4.0%+2.4%
ADCTADC Therapeutics S.A.LTM Mar 2026138.66M +34.3%+17.6%
ALMSAlumis Inc. Common StockLTM Jun 2026115.39M +93.6%+384.0%
BCYCBicycle Therapeutics plcLTM Mar 202669.4M +7.1%+32.7%
FULCFulcrum Therapeutics, Inc.LTM Mar 202666.18M +9.2%+12.1%
OMEROmeros CorporationLTM Mar 202662.97M +8.5%+0.4%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 202659.51M +7.9%+21.4%
PRTAProthena Corporation plcLTM Mar 202653.9M -0.4%+4.4%
Peer median (excluding NMRA) 69.4M+7.9%+21.4%

Competitors are the stored peer set for NMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00668K05M
Gross Profit00(668K)0(5M)
Gross Margin—————
Research & Development212.78M104.75M142.72M200.93M176.07M
Selling, General & Admin24.55M31.12M44.81M62.54M60.09M
Operating Expenses237.32M135.87M187.53M263.46M236.16M
Depreciation & Amortization538K594K668K631K208K
EBITDA(236.77M)(130.31M)(234.99M)(242.98M)(233.37M)
EBITDA Margin—————
Operating Income(237.32M)(135.87M)(188.19M)(263.46M)(241.16M)
Operating Margin—————
Interest Income04.56M16.61M19.93M8.34M
Interest Expense00003.22M
Other Income / Expenses11K4.97M(47.46M)19.86M4.36M
Income Before Tax(237.31M)(130.9M)(235.66M)(243.61M)(236.8M)
Pre-Tax Margin—————
Income Tax Expense00268K178K130K
Net Income(237.31M)(130.9M)(235.93M)(243.79M)(236.93M)
Net Margin—————
EPS (Basic)(1.56)(0.86)(1.49)(1.53)(1.45)
EPS (Diluted)(1.56)(0.86)(1.49)(1.53)(1.45)
Weighted Avg Shares151.95M151.95M158.83M159.38M163.39M
Weighted Avg Shares (Diluted)151.95M151.95M158.83M159.38M163.39M

Neumora Therapeutics, Inc. Common Stock

NASDAQ:NMRA

Intrinsic Alpha fair value

Locked

Current Price

$0.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.